28.1 C
Vientiane
Monday, June 30, 2025
spot_img
Home Blog Page 463

WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards

SHANGHAI, April 14, 2025 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pacific Biopharma Excellence Awards (ABEA) ceremony. This also marks the seventh time that the company has been recognized by the organizer.

  • Best Contract Development and Manufacturing Organization Award
  • Best Aseptic Fill-Finish & Packaging CMO of the Year
  • Best Aseptic Fill-Finish & Packaging Supplier Award: Drug Delivery Systems
  • Best New Modalities Manufacturing Company
  • Best Bioprocessing Supplier Award: Cell Line Development & Characterization

WuXi Biologics is committed to advancing integrated technology platforms that accelerate biologics discovery, development, and manufacturing. It has one of the largest portfolios of complex biologics in the industry, including 151 bispecifics & multispecifics, 194 ADCs, 80 fusion proteins and 24 vaccines.The development time for monoclonal antibody projects from DNA to Investigational New Drug (IND) application has been shortened to 9 months, with a recent autoimmune disease project completed in just 6 months. By leveraging single-use technology (SUT), the company scaled manufacturing from 4,000 to 16,000 liters across its global facilities, achieving a 99% success rate (2022-2024). Given the equivalent scale, the SUT manufacturing costs are comparable to those of stainless steel systems. These milestones are underpinned by its world-class quality systems, which have ensured a 100% success rate in Pre-License Inspections (PLI) and have passed 42 inspections by global regulatory agencies, including 22 conducted by the U.S. FDA and EMA.

WuXi Biologics’ high-yielding mammalian cell line platform WuXia™ (up to about 11 g/L) has been widely accepted in the industry and regulatory agencies worldwide. It has generated over 900 cell lines expressing monoclonal and bispecific antibodies, fusion proteins, enzymes and other recombinant proteins for clinical and commercial manufacturing. It has also launched WuXiaADCC Plus™, a superior-performing and high-yielding mammalian cell line platform for the development and manufacturing of afucosylated antibodies to elicit an enhanced ADCC response, and WuXia RidGS™, a high-yield glutamine synthetase (GS)-knockout CHO expression system, catering to the diverse needs of global clients.

WuXi Biologics delivers advanced drug product (DP) development services for biologics, vaccines and small molecule parenterals. Its capabilities include the development of liquid, frozen, and lyophlized dosage forms, complemented by proficiency in diverse container closure systems (CCS) that include vials and combination products such as pre-filled syringes (PFS), PFS with needle safety devices (NSD) and autoinjectors. Furthermore, the company operates multiple state-of-the-art DP manufacturing facilities for the formulation, filling, labelling, and packaging of biotherapeutics, vaccines, placebo and parenterals filled into either liquid or lyophilized dosage forms.

Dr. Chris Chen, CEO of WuXi Biologics, commented, “The numerous accolades earned by WuXi Biologics stand as a powerful testament to the value we deliver to global clients and the broader industry. Through our relentless pursuit of excellence, uncompromising quality standards, visionary leadership, and the dedication of our talented global team, we remain steadfast in enabling partners to accelerate groundbreaking therapies—bringing life-changing treatments to patients around the world.”

Sponsored by IMAPAC, a leading consulting firm in the biopharmaceutical industry, the ABEA seeks to recognize the outstanding achievements of top leaders in biomanufacturing, biologistics and clinical trials, applauding extraordinary leaders and trendsetters of today, and inspiring innovators of tomorrow. Finalists for each award category are shortlisted based on the volume of nominations received and a rigorous internal evaluation of merit. The ultimate winners are determined by votes from the global biopharma community, ensuring an unbiased and industry-driven outcome.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

Contacts 
 
Media 
PR@wuxibiologics.com

Business
info@wuxibiologics.com

 

Crowd Favorite from CES and MWC 2025, Aurzen ZIP Projector, Now Available

IRVINE, Calif., April 14, 2025 /PRNewswire/ — After generating significant excitement and acclaim at CES and MWC 2025, ZIP ultra-portable projector is now available in the United States and Canada.

The World's First Tri-Fold Truly Portable Projector
The World’s First Tri-Fold Truly Portable Projector

Praised by attendees and technology reviewers alike for its innovative design and functionality, the Aurzen ZIP captured significant attention at CES 2025. Key highlights include its compact, tri-fold adjustable design, native 720p HD resolution, effortless zero-lag autofocus, automatic keystone correction, and wireless mirroring compatibility with both iOS and Android devices. The built-in rechargeable battery ensures up to 1.5 hours of continuous entertainment, enhanced further with rapid PD fast charging.

ZIP Key Features:

  • DLP Display – 100 ANSI lumens – 720p
  • Pocket Size – 3.3 x 3.1 x 1 inch – 9.8 oz / 84 x 78 x 26mm – 280g
  • Instant Setup – Autofocus and Keystone, 1.5 hour battery, Dual Speakers
  • OS – Android, Windows, iOS, macOS

ZIP’s impressive features and usability have already resonated strongly with early reviewers and YouTube influencers, earning high marks for versatility in indoor and outdoor scenarios such as home cinemas, camping, and on-the-go entertainment. More than a dozen YouTube channels published favorable reviews in the recent months, and many more social media channels raved about the pocket size ZIP. A number of professional projector reviewers have also published favorable reviews recently.

The Aurzen ZIP is now available for purchase with an MSRP of $399.99. Don’t miss your chance to experience the portable projector that captured CES and MWC audiences.

Visit Aurzen’s official website or Amazon to purchase your ZIP projector today.

About Aurzen
Aurzen is an innovative consumer electronics company specializing in home entertainment and lifestyle technology solutions. Aurzen designs and manufactures unique, premium-quality products, including projectors and audiovisual solutions, aimed at enhancing how consumers engage with entertainment, gaming, and digital lifestyles. For more information, please visit Aurzen’s official website and its Amazon Store.

Contact
For inquiries regarding business collaborations or product reviews, please feel free to reach out to us via media@aurzen.com.

 

Celebrating 18 Years of Olight: Illuminating Dreams for 20+ Million Users Globally

SHENZHEN, China, April 14, 2025 /PRNewswire/ — Olight, a global leader in innovative portable lighting solutions with over 20 million users worldwide, proudly marks its 18th anniversary with the launch of three new products and a global storytelling campaign celebrating the deep bonds between users and their trusted light companions.

A full lineup of Olight's iconic innovations celebrates 18 years and 20M+ users worldwide.
A full lineup of Olight’s iconic innovations celebrates 18 years and 20M+ users worldwide.

“Great products create moments, but great communities create legacies.” said Mavis Xiao, CMO of Olight.

Anniversary Campaign: “My First Olight”
The “My First Olight” campaign runs from March 28 to April 28, 2025, inviting fans to share their personal stories and memorable moments with their first Olight products through the Community & Blog platform using the hashtag #My1stOlight. Early submissions reveal powerful stories—from a rookie officer whose entire station switched to Olight based on his recommendation, to a loyal customer who’s gifted over six products across three generations. Whether during hurricane blackouts, roadside emergencies, or family camping trips, Olight has proven itself a trusted companion when light matters most.

The first nine featured stories were announced during Olight’s YouTube livestream on April 12, with the complete list to be revealed on April 30. The 18 most inspiring storytellers will receive exclusive global limited-edition Oclip18 Zirconium rewards.

Innovation Milestones
In 2024, Olight introduced OAL™, the world’s toughest and most wear-resistant aluminum in flashlights. The company expanded beyond lighting with the eco-conscious Ostation X power station, while enhancing its core products with three exceptional new releases:

  • Warrior Ultra: A professional-grade performance-engineered flashlight featuring aerospace aluminum construction, 2,500-lumen output, and operational-grade reliability for critical applications
  • Oclip Ultra: The ultimate EDC companion with smart magnetic charging, adaptive brightness, and modular design for precision illumination anywhere
  • Sphere C: A multi-mode ambiance light offering 360° soft glow, app-enabled color journeys, and smart scene sync for effortless space transformation

Enhanced Customer Experience & Social Impact
Olight’s companion app enables remote device control and access to exclusive rewards. The company also opened its first experience store in Las Vegas, offering hands-on product interaction and expert guidance. With over $4 million donated to disaster relief, autism awareness, and environmental protection initiatives, Olight remains dedicated to corporate social responsibility.

About Olight

Founded in 2007, Olight is the global leader in providing innovative portable lighting products trusted by outdoor enthusiasts worldwide. Olight pushes the boundaries of lighting technology to meet diverse customer needs.

Hankook Tire Powers the 2025 Miami E-Prix to a Thrilling Finish in Formula E Season 11

GEN3 Evo iON Race Tire Shines Under Unpredictable Course Conditions

  • The GEN3 Evo iON Race tire showcases unwavering performance under complex track conditions from high-speed straights to technical corners
  • Hankook Tire strengthens local motorsport fan engagement through its ‘Hankook X FE Tube Shop’ pop-up and ‘Fan Village’ activation
  • The 2025 Monaco E-Prix is scheduled for May 3-4 as the next double-header race for Rounds 6 and 7

MIAMI, April 14, 2025 /PRNewswire/ — Hankook Tire & Technology (Co-CEOs Jong-sun Ahn and Sanghoon Lee), a leading global tire company under Hankook & Company Group and the official partner of the ABB FIA Formula E World Championship (hereafter Formula E), celebrated the successful conclusion of the 2025 Miami E-Prix, the adrenaline-charged fifth round of Season 11, held on April 12 (local time) at Homestead-Miami Speedway in Miami, Florida, USA.

Hankook Tire Sponsored Formula E 2025, Miami E-Prix Successfully Concluded
Hankook Tire Sponsored Formula E 2025, Miami E-Prix Successfully Concluded

All 22 drivers who competed in the race delivered explosive performances and engaged in fierce wheel-to-wheel battles on the Homestead-Miami Speedway — a circuit defined by blistering straights and sudden technical corners. Amidst the fierce competition, the GEN3 Evo iON Race tire, Formula E’s official electric racing tire, once again emerged as a game-changer in race strategy by exemplifying outstanding stability, with consistent grip and agile handling under extreme racing conditions.

Pascal Wehrlein of TAG Heuer Porsche stormed to victory in Round 5 with an impressive 26-point lead. Lucas di Grassi of Lola Yamaha ABT edged out the competition for second place, followed by António Félix da Costa of TAG Heuer Porsche, who rounded out the podium after a hard-fought race to the finish.

In the team championship standings, TAG Heuer Porsche maintains the lead, with Nissan and NEOM McLaren closely trailing, with 79 points and 67 points respectively, intensifying the fight for the crown as the season gains momentum.

Beyond the racetrack, the ‘Hankook X FE Tube Shop’ pop-up store, held from April 9 to 11 on Miami Beach, wrapped up a successful run with strong local engagement — from tire-shaped float rentals and a heavy tire-flipping challenge to an oversized GEN3 Evo iON Race tire installation and photo zones. A steady stream of families and beachgoers flocked to the experience, boosting awareness of Hankook as a unified global brand.

Hankook Tire also operated an immersive brand exhibition in the ‘Fan Village’ for Formula E spectators, showcasing its full iON product lineup — the world’s first dedicated EV tire range — along with the GEN3 Evo iON Race tire. The live showcase invited North American fans to experience Hankook Tire’s leading EV tire technology firsthand.

All eyes now turn to the 2025 Monaco E-Prix, scheduled for May 3 to 4. First established in 1929, the historic Circuit de Monaco — winding through the steep hills and sharp corners of Monte Carlo’s city streets along the Mediterranean coast — is recognized as one of the most iconic and technically demanding street circuits in the Formula E calendar.

NYSE Content Advisory: Pre-Market update: NYSE President reassures U.S. market infrastructure is resilient

NEW YORK, April 14, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

NYSE Content Advisory: Pre-Market update: NYSE President reassures U.S. market infrastructure is resilient

Kristen Scholer delivers the pre-market update on April 14th

  • Policy questions continued over the weekend after comments from President Trump and Commerce Secretary Howard Lutnick.
  • The S&P 500 is up early Monday after tariff adjustments last week led to record volatility on Wall Street.
  • NYSE President Lynn Martin recently assured the trading community that the NYSE has, “met the challenge posed by recent volatility.”

Read NYSE President Lynn Martin’s CNBC Op-ed Here

Opening Bell
MSNBC Films, Sky Studios, Paradine Productions, and White Horse Pictures celebrate the upcoming premiere of documentary series, “David Frost Vs.”

Closing Bell
Executives and guests of IonQ (NYSE: IONQ) celebrate World Quantum Day

Download the NYSE TV App and Subscribe Here 

 

FIRSTHABIT Announces Open Recruitment for 2025, Aiming to Expand Its Global AI Education Market Presence

  • FIRSTHABIT is launching a strategic recruitment drive targeting a double-digit increase in its workforce, aiming to secure top-tier talent to revolutionize the global AI education sector.
  • The company is seeking candidates for 11 roles, including AI Researchers, Global Mathematics Content Researchers, and Service Planners.
  • A key focus of the recruitment effort is on specialists who can advance the research on its proprietary AI model, ‘CHALK AI’, with a strong emphasis on mathematical expertise needed for algorithm modeling.

SEOUL, South Korea and NEW YORK, April 14, 2025 /PRNewswire/ — FIRSTHABIT, formerly known as Seomjae and a pioneer in educational AI, is actively recruiting new and experienced employees in 2025 to spearhead innovation in the global AI education market, aiming to hire talent in double digits.

FIRSTHABIT is actively recruiting new and experienced employees in 2025, aiming to hire talent in double digits.
FIRSTHABIT is actively recruiting new and experienced employees in 2025, aiming to hire talent in double digits.

This recruitment aims to quickly secure outstanding talent in the AI and education sectors who can put their capabilities to use anywhere worldwide, further develop top-notch mathematics content, and boost the technological competitiveness of its proprietary AI model, ‘CHALK AI’. This is part of FIRSTHABIT’s strategy to aggressively expand its footprint as a global AI education platform.

FIRSTHABIT values professional candidates who resonate with its vision of revolutionizing education and are passionate about taking on new challenges. The open positions include AI Researcher, Global Mathematics Content Researcher, Service Planner, Content Director, Business Developer, and 3D Graphic Designer, among 11 roles. Details about the qualifications and preferred attributes for each role are available on the FIRSTHABIT recruitment website.

Specifically, FIRSTHABIT is actively hiring individuals to lead research on ‘CHALK AI’, its core technological initiative. ‘CHALK AI’ is a proprietary model engineered not only to respond to data but to comprehend and interpret complex concepts. Candidates for these roles must possess profound intellectual capacity to define intuitive concepts mathematically and to develop and optimize algorithms.

FIRSTHABIT employees will benefit from a supportive corporate culture promoting personal growth, including comprehensive support for the necessary equipment and software, generous annual leave, provision of holiday and special occasion stipends, and unrestricted access to mathematics classes along with educational funding. The company aims to provide industry-leading compensation based on past experience.

FIRSTHABIT started as an educational content production company in 2021 and has focused on advancing AI-based technologies since 2023. It is currently developing a hyper-personalized learning solution, ‘CHALK 3.0’, based on its proprietary ‘CHALK AI’ model. ‘CHALK’ is distinguished by its capabilities in high-quality data-based optimal route finding, customized learning content delivery, and a 1:1 AI tutor feature.

‘CHALK 3.0’ demonstrated its sustainability as an effective learning tool by achieving a completion rate of 76.4% during beta tests in Seoul and Boston last year, and it was honored with an innovation award at CES 2025, underscoring its technological excellence. With a team comprising the nation’s top content specialists and AI developers, FIRSTHABIT is rapidly progressing with service planning and anticipates an official launch later this year.

FIRSTHABIT Director of Operations and Business Development Hyunwoo Choi said, “Our company prioritizes growth, challenge, and educational innovation, and we are in search of passionate and responsible talent. We eagerly await applications from those who align with FIRSTHABIT’s values, are ready to develop in tandem with the company and are committed to contributing to the future of AI education with a high level of engagement.”

About FIRSTHABIT

FIRSTHABIT is a global AI education company that aspires to innovate education in the international market through the integration of education and technology. Operating under the vision of ‘Global Education Navigation’, it is developing ‘CHALK 3.0′. This program, built on unique AI technology, addresses the limitations inherent in traditional instructor-centered learning methods by offering educational solutions that are tailored to individual students’ learning styles, dispositions, and objectives. The program efficiently organizes data and links learning components organically to analyze students’ levels and patterns and to formulate optimal learning pathways. Further details about the company and CHALK are available on its website. https://www.firsthabit.com/

 

 

Amcor receives ‘AA’ MSCI ESG rating, recognizing its commitment to sustainability

ZURICH, April 14, 2025 /PRNewswire/ — Amcor (NYSE: AMCR, ASX: AMC), a global leader in developing and producing responsible packaging solutions, has been recognized with an ‘AA’ rating by MSCI ESG Research for its strong sustainability performance. This rating underscores Amcor’s commitment to environmental, social and governance (ESG) leadership and highlights its progress in advancing more sustainable packaging solutions.

Amcor has been recognized with an ‘AA’ rating by MSCI ESG Research for its strong sustainability performance.
Amcor has been recognized with an ‘AA’ rating by MSCI ESG Research for its strong sustainability performance.

Amcor’s ‘AA’ rating highlights the company’s ongoing efforts to reduce greenhouse gas emissions, increase clean energy procurement and expand the use of recycled content in its products. The company’s focus on circular economy solutions is a key pillar of its sustainability strategy, driving innovation to reduce environmental impact and enhance recyclability at a global scale.

David Clark, Chief Sustainability Officer at Amcor, said, “We are proud that MSCI continues to recognize Amcor’s commitment to responsible packaging, and we celebrate this achievement. This rating is a testament to our dedication to delivering superior packaging solutions that meet consumer expectations, customer needs and the highest standards of efficiency and safety. Amcor is focused on advancing our sustainability journey and collaborating with our value chain partners to help shape a society where responsible consumption and circularity are the norm.”

MSCI ESG Research provides ratings on global public and select private companies, assessing their exposure to industry-specific ESG risks and ability to manage those risks relative to peers.

Learn more about Amcor’s sustainability initiatives at Amcor.com.

About Amcor

About Amcor Amcor is a global leader in developing and producing responsible packaging solutions for food, beverage, pharmaceutical, medical, home and personal-care, and other products. Amcor works with leading companies around the world to protect their products and the people who rely on them, differentiate brands, and improve supply chains through a range of flexible and rigid packaging, specialty cartons, closures, and services. The company is focused on making packaging that is increasingly lighter weight, recyclable and reusable, and made using an increasing amount of recycled content. In fiscal year 2022, 44,000 Amcor people generated $15 billion in annual sales from operations that span 220 locations in 43 countries. NYSE: AMCR; ASX: AMC 
www.amcor.com I LinkedIn I YouTube

Vinmec Recognized As Vietnam’s First Allergy & Clinical Immunology Center of Excellence

HANOI, VIETNAM – Media OutReach Newswire – 14 April 2025 – The Center of Allergy and Clinical Immunology under the Vinmec Healthcare System has officially been chosen as a World Allergy Organization (WAO) Center of Excellence (CoE) — making it the first medical facility in Vietnam to receive this prestigious recognition. This milestone marks a significant advancement in the nation’s allergy and clinical immunology, aligning Vietnamese healthcare with international standards.

Vinmec Times City's Immunology – Allergy Center named WAO Center of Excellence
Vinmec Times City’s Immunology – Allergy Center named WAO Center of Excellence

WAO is a preeminent medical institution in the field of allergy and clinical immunology, comprising 115 national and regional member societies across six continents. The WAO COE are distinguished medical facilities recognized for their outstanding achievements in medical practices, education, research, innovation, and international influences.

Following a rigorous multi-stage assessment process — including credentials review, scientific evidence review, and examination of on-site operational capability — Vinmec’s Allergy and Clinical Immunology Center met WAO’s stringent criteria to earn the COE designation. This international recognition not only affirms Vinmec’s expertise in the field but also grants the Center prioritized access to international research collaborations, advanced training and clinical trials, and state-of-the-art treatment modalities through WAO and its global network of leading academic partners.

Assoc. Prof. Dr. Nguyen Van Dinh, Director of the Clinical Allergy and Immunology Center at Vinmec, commented: “Being recognized as a WAO Center of Excellence is a landmark achievement for Vietnam’s allergy and clinical immunology. This recognition enables our clinicians and researchers to gain a better understanding of advancements in allergic diagnosis and treatment, participate in research collaborations, and have access to advanced therapies of the world. It also gives our health professionals an opportunity to receive training and capacity building by world-renowned experts, thus delivering the most optimized and personalized treatments that ensure the safety of patients”.

Prior to the CoE recognition by WAO, Vinmec’s Allergy and Clinical Immunology Center had been the first medical facility in Vietnam to receive dual recognitions in specialized allergy care, including: ADCARE (Atopic Dermatitis Centers of Reference and Excellence) and UCARE (Urticaria Centers of Reference and Excellence).

Vinmec’s Allergy and Clinical Immunology Center is also the first and only healthcare provider in Vietnam licensed by the Ministry of Health to deploy biologic therapies and advanced immunological treatments for severe chronic allergic and immunological disorders — such as bronchial asthma, atopic dermatitis, chronic urticaria, allergic rhinosinusitis with nasal polyps and prurigo nodularis.

Vietnam joins the WAO Centers of Excellence global map
Vietnam joins the WAO Centers of Excellence global map

Vinmec is currently at the forefront of utilizing genetic testing to screen for drug hypersensitivity risks — thereby personalizing the clinical pathway and enhancing patient safety — and applying monoclonal antibody therapies, a cutting-edge and specialized treatment modality typically available only at leading international medical institutions. Additionally, Vinmec has developed comprehensive diagnostic and management protocols for primary immunodeficiency disorders, offering patients early detection, appropriate intervention, and long-term care.

Vinmec now stands among other prestigious WAO Centers of Excellence in the region, including the National University of Singapore, Yonsei University College of Medicine (South Korea), University of Tokyo Hospital (Japan), and Shanghai Jiao Tong University School of Medicine (China).

The WAO’s recognition follows Vinmec’s previous establishment of three internationally accredited Centers of Excellence in Cardiology, Oncology, and Orthopedics & Sports Medicine. These achievements reflect Vinmec’s strategic commitment to building globally recognized centers of excellence that deliver innovative, world-class healthcare solutions to Vietnamese and international patients alike.

Hashtag: #Vinmec

The issuer is solely responsible for the content of this announcement.